Covered recipient · General Payments record
SKYLER T SHARP
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$866.30
- Reported across 51 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.32 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $58.39 | 4 |
| Amgen Inc. | $42.08 | 2 |
| Novo Nordisk AS | $41.10 | 2 |
| Merck Sharp & Dohme Corporation | $27.66 | 1 |
| Exact Sciences Corporation | $23.41 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $20.04 | 1 |
| ABBVIE INC. | $18.85 | 1 |
| GlaxoSmithKline, LLC. | $17.05 | 1 |
| Lilly USA, LLC | $14.59 | 1 |
| Acerta Pharma LLC | $14.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.85 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108181783 | CMS |
| Amgen Inc. | $21.69 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117681772 | CMS |
| Amgen Inc. | $20.39 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117681774 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.15 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104286400 | CMS |
| Boston Scientific Corporation | $20.04 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092343724 | CMS |
| Exact Sciences Corporation | $23.41 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114560905 | CMS |
| GlaxoSmithKline, LLC. | $17.05 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116422141 | CMS |
| Lilly USA, LLC | $14.59 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135955551 | CMS |
| Merck Sharp & Dohme LLC | $27.66 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141764261 | CMS |
| Novo Nordisk Inc | $18.61 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100255576 | CMS |
| Novo Nordisk Inc | $22.49 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100279418 | CMS |
| PFIZER INC. | $13.80 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131033764 | CMS |
| PFIZER INC. | $13.14 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131441422 | CMS |
| PFIZER INC. | $17.48 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131989747 | CMS |
| PFIZER INC. | $13.97 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131121318 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2021 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.